Germany
Japan
United Kingdom
China
Research Areas
View as table Download
USD 465.00
In Stock
Galectin 3 Rabbit monoclonal Antibody
| Applications | IF, WB |
| Reactivities | Human, Monkey, Rat |
| Conjugation | Unconjugated |
Recombinant Anti-CD20 (Clone 10F381 (rituximab))
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD20 (Clone 10F381 (rituximab))
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD20 (Clone 10F381 (rituximab))
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
5 Weeks
Recombinant Anti-IL-2R (Clone Daclizumab)
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
USD 523.00
2 Weeks
Recombinant Anti-IL-2R (Clone Daclizumab)
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD4 (Clone MT310)
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
Recombinant Anti-CD4 (Clone MT310)
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD22 (Clone hL22 (Epratuzumab))
| Applications | Bl, FC, IP |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
Recombinant Anti-CD22 (Clone hL22 (Epratuzumab))
| Applications | Bl, FC, IP |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-PD-L1 (Clone 332M7)
| Applications | FC |
| Reactivities | Human, Monkey, Mouse |
| Conjugation | Unconjugated |
Recombinant Anti-PD-L1 (Clone 332M7)
| Applications | FC |
| Reactivities | Human, Monkey, Mouse |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
CD4 mouse monoclonal antibody, clone OTI10B5 (formerly 10B5)
| Applications | WB |
| Reactivities | Human, Monkey, Rat, Dog |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
CD4 mouse monoclonal antibody, clone OTI9C1 (formerly 9C1)
| Applications | WB |
| Reactivities | Human, Monkey, Rat, Dog |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
Anti-CD5 mouse monoclonal antibody, clone OTI6F7 (formerly 6F7)
| Applications | FC, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
USD 420.00
4 Weeks
USD 420.00
4 Weeks
ANAPC2 (Apc2) mouse monoclonal antibody, clone OTI1A6 (formerly 1A6)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey, Mouse, Rat |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
USD 420.00
5 Days
USD 420.00
5 Days
MAPK9 (JNK2) mouse monoclonal antibody, clone OTI2D11 (formerly 2D11)
| Applications | IHC, WB |
| Reactivities | Human, Monkey, Mouse, Rat, Dog |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
USD 420.00
5 Days
USD 420.00
5 Days
MAPK9 (JNK2) mouse monoclonal antibody, clone OTI2G3 (formerly 2G3)
| Applications | IF, IHC, WB |
| Reactivities | Human, Monkey, Mouse, Rat, Dog |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
USD 420.00
5 Days
Active filters
Reactivities
- Monkey
Clonalities
- Monoclonal
Filter by
Category
Target Symbol
Antibody Hosts
Conjugates
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (5)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
Families
Pathways
- T cell receptor signaling pathway (38)
- Hematopoietic cell lineage (33)
- Cell adhesion molecules (CAMs) (29)
- Progesterone-mediated oocyte maturation (21)
- Primary immunodeficiency (17)
- Colorectal cancer (16)
- ErbB signaling pathway (16)
- Fc epsilon RI signaling pathway (16)
- Focal adhesion (16)
- Insulin signaling pathway (16)
- MAPK signaling pathway (16)
- Neurotrophin signaling pathway (16)
- Pancreatic cancer (16)
- Pathways in cancer (16)
- Type II diabetes mellitus (16)
- Adipocytokine signaling pathway (15)
- Epithelial cell signaling in Helicobacter pylori infection (15)
- GnRH signaling pathway (15)
- NOD-like receptor signaling pathway (15)
- RIG-I-like receptor signaling pathway (15)
- Toll-like receptor signaling pathway (15)
- Wnt signaling pathway (15)
- Antigen processing and presentation (12)
- B cell receptor signaling pathway (6)
- Cell cycle (5)
- Oocyte meiosis (5)
- Prion diseases (5)
- Ubiquitin mediated proteolysis (5)
- Vascular smooth muscle contraction (2)
- Acute myeloid leukemia (1)
- Bladder cancer (1)
- Chemokine signaling pathway (1)
- Chronic myeloid leukemia (1)
- Endometrial cancer (1)
- Fc gamma R-mediated phagocytosis (1)
- Glioma (1)
- Long-term depression (1)
- Long-term potentiation (1)
- Melanoma (1)
- Natural killer cell mediated cytotoxicity (1)
- Non-small cell lung cancer (1)
- Prostate cancer (1)
- Regulation of actin cytoskeleton (1)
- Renal cell carcinoma (1)
- Thyroid cancer (1)
- Tight junction (1)
- mTOR signaling pathway (1)